Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib dose-escalation study of recombinant factor VIIa in congenital hemophilia A or B
NL-OMON36958Phase 1Active, not recruiting
- Sponsor
- rEVO Biologics
- Start
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of Coagulation factor VIIa recombinant human in hemophilia A and hemophilia B (HB) (3 arms), sponsored by rEVO Biologics. Primary endpoints: Terminal half-life, AUC0-t and 10 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
Coagulation factor VIIa recombinant human
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON36958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36958.